Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
GLP-1RA reduces risk of CV events associated with overweight and obesity
GLP-1RA reduces risk of CV events associated with overweight and obesity
Healthy lifestyle interventions for CVD risk reduction in secondary prevention
Healthy lifestyle interventions for CVD risk reduction in secondary prevention
Main messages of new ESC guidelines for CVD management in diabetes
Main messages of new ESC guidelines for CVD management in diabetes
Clinically meaningful benefits with GLP-1RA in HFpEF and obesity
Clinically meaningful benefits with GLP-1RA in HFpEF and obesity
Timing of benefits of intentional weight loss in cardiometabolic disease
Timing of benefits of intentional weight loss in cardiometabolic disease
An urgent call for action to tackle excess adiposity
An urgent call for action to tackle excess adiposity
